-
Publication Venue For
-
Corrigendum to: Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes [Virology 475 (2015) 37-45].
478:155-158.
2015
-
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination..
375:315-320.
2008
-
Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques..
374:322-337.
2008
-
Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system..
374:453-467.
2008
-
Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope..
372:442-456.
2008
-
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine..
369:153-167.
2007
-
Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens..
367:175-186.
2007
-
A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120..
366:245-262.
2007
-
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate..
366:84-97.
2007
-
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains..
364:486-493.
2007
-
Cloning and analysis of microRNAs encoded by the primate gamma-herpesvirus rhesus monkey rhadinovirus..
364:21-27.
2007
-
Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies..
363:79-90.
2007
-
Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge..
362:441-452.
2007
-
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins..
360:218-234.
2007
-
Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells..
358:357-372.
2007
-
Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques..
358:69-78.
2007
-
Contributions of E1A to mouse adenovirus type 1 pathogenesis following intranasal inoculation..
357:54-67.
2007
-
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses..
353:268-282.
2006
-
Ancestral and consensus envelope immunogens for HIV-1 subtype C..
352:438-449.
2006
-
Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine..
352:285-294.
2006
-
Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype..
348:341-353.
2006
-
Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates..
345:44-55.
2006
-
Ceramide regulates SR protein phosphorylation during adenoviral infection.
345:280-289.
2006
-
Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques..
343:246-255.
2005
-
Acute respiratory infection with mouse adenovirus type 1..
340:245-254.
2005
-
Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs..
340:21-32.
2005
-
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif..
339:281-288.
2005
-
Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques..
333:226-238.
2005
-
Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives..
332:623-628.
2005
-
Protein interactions among the vaccinia virus late transcription factors..
329:328-336.
2004
-
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor..
328:163-168.
2004
-
Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope..
328:74-88.
2004
-
Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564..
324:525-530.
2004
-
Post-transcription cleavage generates the 3' end of F17R transcripts in vaccinia virus..
319:1-11.
2004
-
The double-stranded RNA-activated protein kinase mediates viral-induced encephalitis..
317:263-274.
2003
-
Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements..
311:241-253.
2003
-
The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma..
310:100-108.
2003
-
Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6)..
308:178-190.
2003
-
HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest..
305:371-377.
2003
-
Expression of the vaccinia virus A2.5L redox protein is required for virion morphogenesis..
300:296-303.
2002
-
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model..
294:270-281.
2002
-
Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease..
292:137-149.
2002
-
Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation..
288:175-187.
2001
-
Genetic variation in the 3' non-coding region of dengue viruses..
281:75-87.
2001
-
Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis..
273:248-257.
2000
-
Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia..
270:237-249.
2000
-
Glycoprotein B of human herpesvirus 8 is a component of the virion in a cleaved form composed of amino- and carboxyl-terminal fragments..
269:18-25.
2000
-
Analysis of the RNA binding specificity of the human tap protein, a constitutive transport element-specific nuclear RNA export factor..
262:200-209.
1999
-
Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional..
259:7-19.
1999
-
The gamma2 late glycoprotein K promoter of equine herpesvirus 1 is differentially regulated by the IE and EICP0 proteins..
256:173-179.
1999
-
A 43-nucleotide RNA cis-acting element governs the site-specific formation of the 3' end of a poxvirus late mRNA..
255:190-204.
1999
-
Retroviruses as model systems for the study of nuclear RNA export pathways..
249:203-210.
1998
-
Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle..
242:90-98.
1998
-
Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors..
236:316-327.
1997
-
Identification of cis-acting repressor activity within human immunodeficiency virus type 1 protease sequences..
234:253-260.
1997
-
Genome nucleotide lengths that are divisible by six are not essential but enhance replication of defective interfering RNAs of the paramyxovirus simian virus 5..
232:145-157.
1997
-
Identification of regions in HIV-1 Nef required for efficient downregulation of cell surface CD4..
231:231-238.
1997
-
Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting..
230:265-274.
1997
-
Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35)..
226:13-21.
1996
-
Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa..
225:274-281.
1996
-
The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope..
224:415-426.
1996
-
Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha..
223:132-147.
1996
-
Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev..
222:423-429.
1996
-
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1..
219:407-416.
1996
-
The mode of death of pig kidney cells infected with cowpox virus is governed by the expression of the crmA gene..
217:384-391.
1996
-
Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins..
209:347-357.
1995
-
Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators..
206:1150-1154.
1995
-
Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection..
205:82-92.
1994
-
The role of Nef in the replication cycle of the human and simian immunodeficiency viruses..
205:1-6.
1994
-
A single stem-loop structure within the HTLV-1 Rex response element is sufficient to mediate Rex activity in vivo..
204:144-152.
1994
-
Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor..
204:343-356.
1994
-
Patterns of HIV-1 mRNA expression in transgenic mice are tissue-dependent..
202:940-948.
1994
-
Sequence requirements for Rev multimerization in vivo..
202:186-194.
1994
-
Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice..
201:147-151.
1994
-
Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate..
200:623-631.
1994
-
Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge..
200:236-245.
1994
-
Generation of reovirus core-like particles in cells infected with hybrid vaccinia viruses that express genome segments L1, L2, L3, and S2..
197:726-731.
1993
-
Increased expression of alpha 4 beta 1 and alpha 5 beta 1 integrins on HTLV-I-infected lymphocytes..
197:778-781.
1993
-
The eukaryotic translation initiation factor 4E is not modified during the course of vaccinia virus replication..
188:934-937.
1992
-
Evolutionary implications of primate endogenous retroviruses..
182:495-502.
1991
-
Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus..
182:635-643.
1991
-
Transcription of the terminal loop region of vaccinia virus DNA is initiated from the telomere sequences directing DNA resolution..
181:716-720.
1991
-
Does the human immunodeficiency virus Tat trans-activator contain a discrete activation domain?.
178:560-567.
1990
-
Functions of the auxiliary gene products of the human immunodeficiency virus type 1..
178:1-5.
1990
-
Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors..
175:600-604.
1990
-
Transcription of orthopoxvirus telomeres at late times during infection..
175:69-80.
1990
-
Fine structure mapping and phenotypic analysis of five temperature-sensitive mutations in the second largest subunit of vaccinia virus DNA-dependent RNA polymerase..
174:60-69.
1990
-
Inhibition of an inflammatory response is mediated by a 38-kDa protein of cowpox virus..
172:262-273.
1989
-
Inhibitory effects of vesicular stomatitis virus on cellular and influenza viral RNA metabolism and protein synthesis..
172:274-284.
1989
-
The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu 2 and the major nonstructural protein mu NS, respectively..
169:293-304.
1989
-
High-level synthesis of biologically active reovirus protein sigma 1 in a mammalian expression vector system..
167:601-612.
1988
-
The sequence of the reovirus serotype 3 L3 genome segment which encodes the major core protein lambda 1..
167:31-37.
1988
-
The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus..
166:533-541.
1988
-
The coenrichment of stem cells, prothymocytes, and stromal elements with ecotropic retrovirus-producing cells from the bone marrow of leukemia-prone AKR mice..
162:354-361.
1988
-
Replication of the murine cytomegalovirus genome: structure and role of the termini in the generation and cleavage of concatenates..
162:98-107.
1988
-
Tandemly repeated sequences are present at the ends of the DNA of raccoonpox virus..
161:45-53.
1987
-
Persistent coinfection of T lymphocytes with HTLV-II and HIV and the role of syncytium formation in HIV-induced cytopathic effect..
160:372-378.
1987
-
The effects of leukemosuppressive immunotherapy on bone marrow infectious cell centers in AKR mice..
157:387-396.
1987
-
Infection of the HTLV-II-bearing T-cell line C3 with HTLV-III/LAV is highly permissive and lytic..
155:726-731.
1986
-
Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens..
152:459-465.
1986
-
Properties of mouse leukemia viruses: XX. Variation of AKR Substrains in response to antibody therapy..
150:247-251.
1986
-
Conservation of the 3' terminal nucleotide sequences of Ebola and Marburg virus..
149:251-254.
1986
-
Isolation of cowpox virus A-type inclusions and characterization of their major protein component..
149:174-189.
1986
-
RNA sequence and transcriptional properties of the 3' end of the Newcastle disease virus genome..
145:203-212.
1985
-
Base mutations in the terminal noncoding regions of the genome of vesicular stomatitis virus isolated from persistent infections of L cells..
140:249-256.
1985
-
Interactions of plus and minus strand leader RNAs of the New Jersey serotype of vesicular stomatitis virus with the cellular La protein..
135:65-73.
1984
-
Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus..
135:105-117.
1984
-
Transcription in mouse embryo cells permissively infected by murine cytomegalovirus..
131:247-254.
1983
-
Molecular cloning and restriction endonuclease mapping of the murine cytomegalovirus genome (Smith Strain)..
129:94-106.
1983
-
Relatedness by nucleic acid hybridization of new isolates of human T-cell leukemia-lymphoma virus (HTLV) and demonstration of provirus in uncultured leukemic blood cells..
126:688-672.
1983
-
Sequential synthesis of small capped RNA transcripts in vitro by vesicular stomatitis virus..
125:206-218.
1983
-
Cloning of the terminal loop of vaccinia virus DNA..
124:215-217.
1983
-
Intracellular cleavage of an SSV coded gag-related protein..
123:229-234.
1982
-
Sequence at both termini of the 10 genes of reovirus serotype 3 (strain Dearing)..
121:307-319.
1982
-
The sequence at the termini of four genes of the three reovirus serotypes..
121:320-326.
1982
-
Superimmunity: characterization of a new gene in the immunity region of P1..
120:360-375.
1982
-
XVIII. Effective treatment of AKR leukemia with antibody to gp7 1 eliminates the neonatal burst of ecotropic AKR virus producing cells..
119:68-81.
1982
-
Association of 3' terminal RNA sequences with avian leukosis viruses causing a high incidence of osteopetrosis..
116:163-180.
1982
-
Identification of a 20,000-dalton protein in SSV-transformed nonproducer cells..
115:401-405.
1981
-
Clonal isolate of the simian sarcoma virus codes for a Gag-related 65,000-dalton protein..
114:124-131.
1981
-
Detection of a transformation-specific glycopeptide in SSV-infected cells..
112:642-650.
1981
-
Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71..
111:568-578.
1981
-
Interspecies reactivity of type C and D retrovirus p 15E and p 15C proteins..
111:270-274.
1981
-
The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface..
108:147-155.
1981
-
The normal organization of the lateral posterior nucleus in the golden hamster and its reorganization after neonatal superior colliculus lesions.
113:223-238.
1981
-
Nature of the 3'-terminal sequences of the plus and minus strands of the S1 gene of reovirus serotypes 1, 2 and 3..
105:41-51.
1980
-
The plus strand of reovirus gene S2 is identical with its in vitro transcript..
105:282-286.
1980
-
Evidence that the src gene product of Rous sarcoma virus is membrane associated..
101:25-40.
1980
-
Further characterization of the oncornavirus inactivating factor in normal mouse serum..
98:20-34.
1979
-
Properties of mouse leukemia viruses. XVI. Suppression of spontaneous fetal leukemias in AKR mice by treatment with broadly reacting antibody against the viral glycoprotein gp 71..
93:159-174.
1979
-
Effects of the src gene product on microfilament and microtubule organization in avian and mammalian cells infected with the same temperature-sensitive mutant of Rous sarcoma virus..
92:201-210.
1979
-
B-MuX: a unique murine C-type virus containing the "env" gene of xenotropic viruses and the "gag" gene of the ecotropic virus..
90:255-264.
1978
-
Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus..
90:241-254.
1978
-
Normal chicken cells (chf-) express a surface antigen which cross-reacts with determinants of the major envelope glycoprotein (gp85) of avian myeloblastosis virus..
86:205-216.
1978
-
Influence of antisera to oncornavirus glycoprotein (gp71) on infections of cats with feline leukemia virus..
85:617-621.
1978
-
An analysis of type-C retrovirus polypeptides and their associations in the virion..
84:19-31.
1978
-
Properties of mouse leukemia viruses. XIV. Prevention of spontaneous AKR leukemia by treatment with group-specific antibody against the major virus gp71 glycoprotein..
83:207-210.
1977
-
Effect of interferon on murine leukemia virus infection. II. Synthesis of viral components in exogenous infection..
79:1-13.
1977
-
Polypeptides of endogenous avian C-type viruses: their detection in the plasma membrane of normal and infected cells..
78:511-521.
1977
-
Properties of mouse leukemia viruses. XIII. Serum therapy of virus-induced murine leukemias..
75:401-418.
1976
-
Characterization of the immune response to the major glycoprotein (gp 71) of Friend leukemia virus. I. Response in BALB/c mice..
75:74-87.
1976
-
Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. II. Response in C57BL/6 mice..
75:88-101.
1976
-
Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. III. Influence on endogenous MuLV-mediated pathogenesis..
75:102-112.
1976
-
Inactivation of murine xenotropic oncornavirus by normal mouse sera is not immunoglobulin-mediated..
71:346-351.
1976
-
Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus..
71:169-184.
1976
-
A comparison of the extents of methylation of vesicular stomatitis virus messenger RNA..
69:364-367.
1976
-
Polypeptides of mammalian oncornaviruses. IV. Structural components of murine leukemia virus released as soluble antigens in cell culture..
68:550-555.
1975
-
Group-specific antigenic determinants of the large envelope glycoprotein of avian oncornaviruses..
67:234-241.
1975
-
Viral glycoprotein synthesis under conditions of glucosamine block in cells transformed by avian sarcoma viruses..
66:347-355.
1975
-
The initial nucleotide sequence of DNA transcribed from avian myeloblastosis virus 70 S RNA by RNA-dependent DNA polymerase..
65:163-172.
1975
-
Comparative chemical properties of avian oncornavirus polypeptides..
64:339-348.
1975
-
Immunological properties of avian oncornavirus polypeptides..
64:349-357.
1975
-
Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity..
63:48-59.
1975
-
Polypeptides of mammalian oncornaviruses. II. Characterization of a murine leukemia virus polypeptide (p15) bearing interspecies reactivity..
63:48-59.
1975
-
Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody..
63:60-67.
1975
-
A proposed nomenclature for the virion proteins of oncogenic RNA viruses..
60:595-600.
1974
-
Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures..
56:549-564.
1973
-
Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses..
56:565-579.
1973
-
Gene A of X174. 1. Isolation and identification of its products..
50:381-387.
1972
-
Polypeptides of avian RNA tumor viruses. IV. Components of the viral envelope..
47:551-566.
1972
-
Polypeptides of avian RNA tumor viruses. V. Analysis of the virus core..
47:567-578.
1972
-
Properties of mouse leukemia viruses. II. Isolation of viral components..
47:210-228.
1972
-
Polypeptides of avian RNA tumor viruses. 3. Purification and identification of a DNA synthesizing enzyme..
45:298-302.
1971
-
Isolation and characterization of two group-specific antigens from feline leukemia virus..
44:73-82.
1971
-
Studies on the reproductive and cell-converting abilities of avian sarcoma viruses..
43:427-441.
1971
-
Size differences among the high molecular weight RNA's of avian tumor viruses..
43:214-222.
1971
-
Polypeptides of avian RNA tumor viruses. 1. Isolation and physical and chemical analysis..
42:1097-1112.
1970
-
Polypeptides of avian RNA tumor viruses. II. Serological characterization..
42:1113-1126.
1970
-
Corrigendum to "Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies" [Virology 363 (2007) 79-90] (DOI:10.1016/j.virol.2007.01.015).
368:431.
2007
-
Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA.
2002